- recruitingTherapeutic exploratory (Phase II)
Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial
The MEMBRAINS study looks at how well modern cancer treatments work for people with advanced melanoma that has spread to the brain. It focuses on patients who also need steroid medicines to reduce brain swelling, helping doctors discover the most effective ways to treat this specific group.
Denmark - recruitingTherapeutic exploratory (Phase II)
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
This study looks at a new drug, RO7198457, combined with an existing drug, Keytruda, for advanced melanoma. We want to see if this combination works better than Keytruda alone to slow down cancer growth and improve patients' lives, while also checking for any side effects.
Spain · Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
France · Norway · Spain - recruitingPHASE3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
This study looks at a new drug, tebentafusp, for people with advanced melanoma that has already been treated. We want to see if tebentafusp, alone or with another drug called pembrolizumab, works better and is safer than standard treatments or best supportive care.
United States · Australia · Austria - not yet recruitingPHASE3
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
This study looks at a new vaccine, iSCIB1+, for advanced skin cancer (melanoma). It wants to see if adding iSCIB1+ to standard immunotherapy (Nivolumab and Ipilimumab) helps people live longer and improves their health. Participants will get either the vaccine or a dummy treatment.
United States · United Kingdom - active not recruitingPHASE2
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
This study is looking at a new treatment called botensilimab, sometimes with another drug called balstilimab, for advanced melanoma. It aims to see how well these drugs work, if they are safe, and how the body handles them in people whose melanoma hasn't responded to previous treatments.
United States · Belgium · Brazil - recruitingPHASE3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
This study is looking into a new treatment called brenetafusp, combined with nivolumab, for advanced melanoma. We're comparing it to current standard nivolumab treatments to see if it works better for people in the UK whose melanoma hasn't been treated before.
United States · Argentina · Australia - recruitingPHASE2, PHASE3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
This study is looking at a new treatment called EIK1001 when given with standard treatment (Pembrolizumab) for advanced melanoma. It aims to see if this combination is safe and effective compared to Pembrolizumab alone for people whose melanoma has spread.
United States · Australia · Austria - recruitingPHASE3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
This study looks at a new treatment called VO with nivolumab for advanced melanoma that has grown despite earlier treatments. It compares this combination to standard treatments chosen by your doctor for people aged 12 and over.
United States · France · Germany